NCT06989983View on ClinicalTrials.gov

A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

June 25, 2025

Study Completion Date

June 25, 2025

Conditions

Heart Failure

Interventions

DRUG

AZD5462 film-coated tablet

Oral, fasted

DRUG

[14C]AZD5462 Solution for Infusion

Intravenous, fasted

DRUG

[14C]AZD5462 Oral Solution

Oral, fasted

Trial Locations (1)

NG11 6JS

Research Site, Ruddington

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Quotient Sciences

INDUSTRY

lead

AstraZeneca

INDUSTRY